Approval · Notice of Compliance 22485 · 2019
EMGALITY: Notice of Compliance 22485
Issued July 30, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22485
- Date
- July 30, 2019
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- GALCANEZUMAB 120 MG per ML